Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1963 1
1965 4
1980 1
1981 2
1982 1
1983 3
1984 4
1985 3
1986 1
1987 1
1988 1
1989 3
1990 5
1991 4
1992 1
1993 6
1994 12
1995 4
1996 8
1997 9
1998 14
1999 13
2000 15
2001 13
2002 17
2003 32
2004 31
2005 46
2006 30
2007 66
2008 84
2009 73
2010 85
2011 90
2012 94
2013 89
2014 126
2015 117
2016 147
2017 153
2018 142
2019 144
2020 167
2021 171
2022 207
2023 199
2024 202
2025 160
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,506 results

Results by year

Filters applied: . Clear all
Page 1
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Mok TS, et al. Among authors: wu yl. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692680 Free article. Clinical Trial.
Consensus on the lung cancer management after third-generation EGFR-TKI resistance.
Zhou Q, Zhao H, Lu S, Cheng Y, Liu Y, Zhao M, Yu Z, Hu C, Zhang L, Yang F, Zhao J, Guo R, Ma R, Du Y, Dong X, Cui J, Tan DSW, Ahn MJ, Tsuboi M, Maggie Liu SY, Mok TS, Wu YL. Zhou Q, et al. Among authors: wu yl. Lancet Reg Health West Pac. 2024 Dec 11;53:101260. doi: 10.1016/j.lanwpc.2024.101260. eCollection 2024 Dec. Lancet Reg Health West Pac. 2024. PMID: 39759798 Free PMC article. Review.
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: wu yl. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. Among authors: wu yl. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.
Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, Chen Y, Gong Y, Lu HL, Lin JT, Yin K, Jiang BY, Nie Q, Liao RQ, Dong S, Guan Y, Dai P, Zhang XC, Yang JJ, Tu HY, Xia X, Yi X, Zhou Q, Zhong WZ, Yang XN, Wu YL. Zhang JT, et al. Among authors: wu yl. Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486. Cancer Discov. 2022. PMID: 35543554 Free PMC article.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Shaw AT, et al. Among authors: wu yl. N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1. N Engl J Med. 2013. PMID: 23724913 Free article. Clinical Trial.
2,506 results